GlassScriptPhysician profile
Matthew S Thomas
NPI 1801862313
$1,026.29
in general payments reported to CMS, 2019-2025
12 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $93.33 · 2022: $17.27 · 2023: $300 · 2024: $199 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $491.28 | 2022-2025 | Epclusa |
| Abbvie INC. | $183.30 | 2019-2023 | Mavyret |
| Braeburn INC. | $100.75 | 2024-2025 | Brixadi |
| Acadia Pharmaceuticals INC | $75.91 | 2019 | |
| Alkermes, INC. | $50.60 | 2019-2025 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.46 | 2024 | Ofev |
| Indivior INC. | $22.55 | 2025 | Sublocade |
| Lilly USA, LLC | $22.33 | 2024 | Zepbound, Mounjaro |
| Sun Pharmaceutical Industries INC. | $17.31 | 2019 | |
| Corcept Therapeutics | $14.68 | 2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $11.22 | 2020 | |
| Mdd US Operations, LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.